P Glycoprotein (ABCB1) Human shRNA Lentiviral Particle (Locus ID 5243)

CAT#: TL315032V

ABCB1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL315032A virus into HEK293 cells. TL315032A virus was prepared using lenti-shRNA TL315032A and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL315032B virus into HEK293 cells. TL315032B virus was prepared using lenti-shRNA TL315032B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL315032C] virus into HEK293 cells. [TL315032C] virus was prepared using lenti-shRNA [TL315032C] and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL315032D] virus into HEK293 cells. [TL315032D] virus was prepared using lenti-shRNA [TL315032D] and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 5243
• Synonyms: ABC20; CD243; CLCS; GP170; MDR1; p-170; P-GP; PGY1
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_000927, NM_001348944, NM_001348945, NM_001348946, NM_000927.1, NM_000927.2, NM_000927.3, NM_000927.4, BC130424
• UniProt ID: P08183
• Summary: The membrane-associated protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the MDR/TAP subfamily. Members of the MDR/TAP subfamily are involved in multidrug resistance. The protein encoded by this gene is an ATP-dependent drug efflux pump for xenobiotic compounds with broad substrate specificity. It is responsible for decreased drug accumulation in multidrug-resistant cells and often mediates the development of resistance to anticancer drugs. This protein also functions as a transporter in the blood-brain barrier. Mutations in this gene are associated with colchicine resistance and Inflammatory bowel disease 13. Alternative splicing and the use of alternative promoters results in multiple transcript variants. [provided by RefSeq, Feb 2017]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).